High blood pressure drug trial halted after just one patient

NCT ID NCT06780033

Terminated Disease control Sponsor: Arnatar Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This was a very early Phase 1 study testing a single injection of ART101 in people with high blood pressure. The trial was stopped after only 1 participant was enrolled, so no meaningful results are available. The goal was to check safety and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ART101 (injected drug)
What this could lead to: If successful, ART101 could offer a new way to lower blood pressure with a single injection.
What could go wrong: This was a very early Phase 1 trial that was terminated after only 1 participant. It is too small and incomplete to draw any conclusions about safety or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION

Contacts and locations

Locations

CMAX Clinical Research Central

Adelaide, South Australia, 5000, Australia
CMAX Clinical Research Fusion

Norwood, South Australia, 5067, Australia
University of Sunshine Coast

Morayfield, Queensland, 4506, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.